Investigating how a specific protein contributes to brain damage in Alzheimer's and related conditions
Cis proline directed proteotoxicity in the early development and therapy of traumatic brain injury and vascular dementia
This study is looking at how a specific form of a protein called cis P-tau might contribute to Alzheimer's disease and other brain issues, especially after injuries or reduced blood flow, to find new ways to protect brain cells and improve treatments for people affected by these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11142679 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific protein conformation, known as cis P-tau, in the development of Alzheimer's disease and related conditions like traumatic brain injury and vascular dementia. The study aims to explore how brain injuries and reduced blood flow to the brain can lead to the formation of this harmful protein. By examining the cellular responses and potential protective mechanisms in neurons, the research seeks to identify new therapeutic strategies that could prevent or mitigate neurodegeneration. The approach includes genetic screening and evaluating the effects of inhibiting certain proteins in laboratory models and potentially in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals experiencing early symptoms of Alzheimer's disease, traumatic brain injury, or vascular dementia.
Not a fit: Patients with advanced stages of Alzheimer's disease or those who do not have any neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of Alzheimer's disease and related neurodegenerative disorders.
How similar studies have performed: Other research has shown promise in targeting similar protein pathways for neurodegenerative diseases, indicating that this approach could be effective.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Qiu, Chenxi — Beth Israel Deaconess Medical Center
- Study coordinator: Qiu, Chenxi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.